Laboratory of Endocrinology, Biomedical Research Center (CINBIO), University of Vigo, Vigo, Spain.
Laboratory of Neuroscience, Biomedical Research Center (CINBIO), University of Vigo, Vigo, Spain.
Vitam Horm. 2022;118:457-478. doi: 10.1016/bs.vh.2021.12.005. Epub 2022 Feb 4.
The glucagon-like peptide-1 (GLP-1) is a pleiotropic hormone very well known for its incretin effect in the glucose-dependent stimulation of insulin secretion. However, GLP-1 is also produced in the brain, and it displays critical roles in neuroprotection by activating the GLP-1 receptor signaling pathways. GLP-1 enhances learning and memory in the hippocampus, promotes neurogenesis, decreases inflammation and apoptosis, modulates reward behavior, and reduces food intake. Its pharmacokinetics have been improved to enhance the peptide's half-life, enhancing exposure and time of action. The GLP-1 agonists are successfully in clinical use for the treatment of type-2 diabetes, obesity, and clinical evaluation for the treatment of neurodegenerative diseases.
胰高血糖素样肽-1（GLP-1）是一种多功能激素，因其在葡萄糖依赖性刺激胰岛素分泌方面的肠促胰岛素作用而广为人知。然而，GLP-1 也在大脑中产生，并且通过激活 GLP-1 受体信号通路在神经保护中发挥关键作用。GLP-1 增强海马体的学习和记忆，促进神经发生，减少炎症和细胞凋亡，调节奖励行为，并减少食物摄入。其药代动力学已得到改善，以增强肽的半衰期，增强暴露和作用时间。GLP-1 激动剂已成功用于治疗 2 型糖尿病、肥胖症，并正在进行治疗神经退行性疾病的临床评估。
